Drugs / Denagliptin
Denagliptin
also known as
DEN · Denagliptin tosilate · DENAGLIPTIN TOSYLATE · Denagliptina · Denagliptine · GW823093 · GW823093C
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00111800 | Apr 2005 → Jul 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00387972 | May 2006 → Oct 2007 | type 2 diabetes mellitus | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00370942 Comparator | Apr → Nov 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | denagliptin | “A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin,...” NCT00111800 ↗ |
| Known as | DEN | “Participants received oral dose of matching placebo capsule to denagliptin (DEN) once daily in the morning, 30 minutes (min) prior to breakfast during the main phase 12-weeks...” NCT00111800 ↗ |
| Known as | Denagliptin tosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110666 ↗ |
| Known as | DENAGLIPTIN TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110666 ↗ |
| Known as | Denagliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110666 ↗ |
| Known as | Denagliptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110666 ↗ |
| Known as | GW823093 | “denagliptin (GW823093)” NCT00387972 ↗ |
| Known as | GW823093C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00370942 ↗ |
| Modality | Small molecule | — CHEMBL2110666 ↗ |
| Route | Oral | “Administered Orally” NCT00111800 ↗ |